Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MAGNE-B6 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment Sequence Group 1 | EXPERIMENTAL | - |
| Treatment Sequence Group 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MAGNE-B6 Oral Solution | DRUG | Oral solution. |
| MAGNE-B6 New Formulation Tablet | DRUG | New formulation tablet. |
Inclusion Criteria: 1. Male or female participants, between 18 and 45 years of age, inclusive. 2. Body weight between 50.0 and 100.0 kg, inclusive, if male, and between 40.0 and 90.0 kg, inclusive, if female, body mass index (BMI) between 18.0 and 30.0 kilogram per square meter (kg/m\^2), inclusive...
MAGNE-B6 is an investigational small molecule being studied in healthy volunteers. It is being evaluated in a Phase 1 clinical trial to assess the bioavailability of a new formulation. The drug is not approved and remains in clinical development.
MAGNE-B6 is being developed by Sanofi, a company listed on the stock exchange under the ticker SNY. Sanofi is conducting clinical research on this investigational drug, which is currently in Phase 1 development.
MAGNE-B6 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied in healthy volunteers to evaluate its bioavailability.
MAGNE-B6 has one completed Phase 1 clinical trial, identified as NCT06386211. This study, titled 'Bioavailability Study of Magne-B6 New Formulation,' enrolled 24 healthy volunteers in Turkey and was a controlled, randomized trial.
MAGNE-B6 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The drug is being studied in healthy volunteers to assess the bioavailability of a new formulation, and it has not completed the clinical trial process.